tbuckley/cabot-search huggingface dataset:
Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis
Authors: Andrew M. Evens, Ranjana Advani, Izidore S Lossos, Oliver W. Press, Julie M Vose, Francisco J. Hernandez-Ilizaliturri, Barrett K Robinson, Stevie Otis, Liat Nadav Dagan, Ramsey Abdallah, Aimee Kroll, Jose Sandoval, Jessica L Yarber, Kelley V. Foyil, Linda M Parker, Leo I. Gordon, John P. Leonard, Thomas M. Habermann, Nancy L. Bartlett
Journal: Blood (2011)
Announcing the New JAMAOncology.com
Authors: Paul Gee, Colleen Kelly, Michael Berkwits
Journal: JAMA Oncology (2016)

the 50% positivity cutoff used to define PTEN loss may have been too generous.Requiring a more complete loss of staining might yield a more accurate but perhaps less sensitive indicator of PI3K activation.This may explain why PTEN loss assessed using immunohistochemical analysis was sometimes found in cancers with other PI3K pathway mutations.Mutations in PIK3CA, AKT1, and PTEN also were less frequently found in cancers with mutations in the DNA guardian, TP53.This observation might seem counterintuitive because increased genome instability might facilitate development and selection of advantageous mutations.However, TP53 is mutated less frequently in tumors that express ER, PR, and/or AR, and PI3K genes are more frequently mutated in such tumors.This suggests that selection of PI3K mutations occurs more because they are strongly advantageous to tumors that depend on high hormonal signaling than because loss of genome stability enables their selection.Tumors with PI3K pathway mutations, high expression of ER, PR, or AR, and wild-type TP53 seem to be particularly interesting candidates for PI3K pathway targeted therapies.Overall, Millis et al 6 have assessed the frequency of mutations in 47 genes, including PIK3CA, PTEN, and AKT1, in 19 784 consecutive diverse solid tumors from 60 countries using targeted massively parallel sequencing.They identify several cancer types in which PI3K pathway genes are present at high frequency that should be considered as candidates for PI3K pathway-targeted drugs.The use of immunohistochemical analysis to assess PTEN loss is novel, but additional work may be needed to define a scoring threshold that accurately identifies tumors in which PI3K signaling is aberrant.It is unfortunate that outcome information was not available for the Millis et al 6 study and that more PI3K pathway genes (eg, AKT2, PIK3R1) were not sequenced.Future studies might be designed to collect this information in order to further our understanding of the impact of PI3K pathway genes on cancer biology and treatment.
TEL-AML1 Affects the Regulation of Cytoskeleton and Causes Alteration In Cellular Adhesive and Migratory Properties In An In Vitro Model of Pre-Leukemia.
Authors: Chiara Palmi, Grazia Fazio, Ilaria Brunati, Valeria Cazzaniga, Valentina André, Silvano Sozzani, Antonello Villa, Anthony Ford, Mel Greaves, Andrea Biondi, Giovanni Cazzaniga
Journal: Blood (2010)
Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia
Authors: Hongtao Liu, Ernesto Diaz-Flores, Xavier Poiré, Olatoyosi Odenike, Greg Koval, Greg Malnassy, Pamela Ihonor, Yanming Zhang, Michelle M. Le Beau, Kevin Shannon, Wendy Stock
Journal: Blood (2010)
Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.
Authors: F. Heidel, F. Breitenbuecher, T. Kindler, F. K. Solem, B. Carius, H.-M. Thiede, P. S. Cohen, J. Roesel, E. H. Estey, E. Feldman, G. Ehninger, G. J. Schiller, V. Klimek, S. Nimer, D. DeAngelo, F. Giles, R. M. Stone, C. Huber, T. Fischer
Journal: Blood (2004)
Use of the Psychosocial Index: A Sensitive Tool in Research and Practice
Authors: Antonio Piolanti, Emanuela Offidani, Jenny Guidi, Sara Gostoli, Giovanni A. Fava, Nicoletta Sonino
Journal: Psychotherapy and Psychosomatics (2016)

The Psychosocial Index (PSI) is a self-rating scale based on clinimetric principles that is simple to use in a busy clinical setting. It can be integrated by observer-rated clinical judgment, providing a first-line, comprehensive assessment of stress, well-being, distress, illness behavior, and quality of life. By calculation of scores, it can be used for conventional psychological measurements. Its clinical applications and clinimetric properties are reviewed. The present version of the PSI has been slightly revised. In addition, a modified version for use in adolescents and young adults (PSI-Young; PSI-Y) is also included.Articles that involved the use of the PSI were identified by searching the Web of Science database from 1998 to February 2016 and by a manual search of the literature.A total of 20 studies reporting results from the use of PSI were included. The PSI has been employed in various clinical populations in different countries and showed high sensitivity. It significantly discriminated varying degrees of psychosocial impairment in different populations. When subjects were identified by categorical criteria (presence of allostatic overload, psychosomatic syndromes, psychiatric disorders), the PSI scores were significantly different across subgroups.In clinical practice, scanning the list of symptoms allows clinicians to assess rapidly which symptoms and problems are perceived as most troublesome. In research settings, the use of scores makes the PSI a valid and sensitive tool in differentiating levels of psychosocial variables among groups.
Kidney Tumor in a von Hippel-Lindau (VHL) Patient With Intensely Increased Activity on 68Ga-DOTA-TATE PET/CT
Authors: Georgios Z. Papadakis, Corina Millo, Samira M. Sadowski, Ulas Bagci, Nicholas J. Patronas
Journal: Clinical Nuclear Medicine (2016)

Renal and pancreatic cysts and tumors are the most common visceral manifestations of von Hippel-Lindau (VHL) disease, a heritable multisystem cancer syndrome characterized by development of a variety of malignant and benign tumors. We report a case of a VHL patient with multiple renal cystic and complex cystic/solid lesions. The patient underwent Ga-DOTA-TATE-PET/CT showing intensely increased activity by a solid lesion which demonstrated enhancement on both CT and MRI scans, raising high suspicion for malignancy. The presented case indicates application of SSTR-imaging using Ga-DOTA-conjugated peptides in VHL-patients and emphasizes the need for cautious interpretation of renal parenchyma Ga-DOTATATE activity.
Adult ALL Patients Treated with Pediatric Inspired Trials Have Inacceptable Early Death but Better Relapse Free Survival Compared to Adult Trials: A Tunisian Single Center Experience
Authors: Hend Ben Neji, Yosr Ben Abdennebi, Lamia Aissaoui, Ramzi Jeddi, Mohamed Zarrouk, Ramzi Ben amor, Karima Kacem, Raihane Ben Lakhal, Zaher Belhadj Ali, Hela Ben Abid, Balkis Meddeb
Journal: Blood (2012)
TCT-151 Cross-sectional Psoas Muscle Area Detected by Computed Tomography as a Measure of Frailty and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Mike Saji, Gorav Ailawadi, Patricia A. Conant, Emily Downs, John Kern, John Dent, Michael Ragosta, Scott Lim
Journal: Journal of the American College of Cardiology (2015)
Cellular Mechanisms For Transferrin Receptor Endocytosis Vital For Terminal Erythroid Differentiation
Authors: Yuichi Ishikawa, Silvia K Tacheva-Grigorova, Manami Maeda, Francois Aguet, Sung-Uk Lee, Maria Ericsson, Tomas Kirchhausen, Takahiro Maeda
Journal: Blood (2013)
TCT-760 A Meta-Analysis of Embolic Protection Devices in the Prevention of Cerebrovascular Events after Transcatheter Aortic Valve Replacement
Authors: Mohammad M. Ansari, Rhanderson N. Cardoso, Daniel C. Garcia, Marco Spaziano, Eduardo de Marchena, Derek Brinster, S Jacob Scheinerman, Giuseppe Martucci, Nicolo Piazza
Journal: Journal of the American College of Cardiology (2015)
TCT-490 Syntax 5-Year Outcomes - Does Geographical Variability Impact Treatment Effects?
Authors: Andrew K. Roy, Bernard Chevalier, Thierry Lefevre, Patrick W. Serruys, Keith D. Dawkins, A. Pieter Kappetein, Friedrich-Wilhelm Mohr, Antonio Colombo, Ted Feldman, Marie-Claude Morice
Journal: Journal of the American College of Cardiology (2015)
PTH-295 Diagnosis of bowel cancer; most patients don’t require whole colonic imaging (WCI); are nice guidelines misleading?: Abstract PTH-295 Table 1
Authors: MR Thompson, K Flashman, D O’Leary, A Senapati
Journal: Gut (2015)

<h3>Introduction</h3> NICE guidelines imply that most patients require WCI for bowel cancer diagnosis. This and fear of missing cancer in outpatients is the major reason for over investigation of patients with bowel symptoms. Greater understanding of the way proximal bowel cancer presents is required. <h3>Method</h3> Retrospective cohort analysis using clinical data collected prospectively for 22 years (1986 to 2007) in a colorectal outpatient clinic in Portsmouth. 29005 patients were analysed to determine symptom combinations, signs and IDA according to site of the colon. Missed cancers were identified from referral back to clinic, local audit and comparison with the regional Cancer Registry. <h3>Results</h3> 1626 patients had cancer of which 1585 presented with one of three bowel symptoms (change in bowel habit, rectal bleeding or abdominal pain). Only 16% (258/1585) were cancers proximal to the sigmoid colon, of which 44% (113/258) presented with symptoms alone (no IDA, no mass), 223 (113/25191) patients would need WCI to diagnose one proximal cancer in this group. Diagnostic yield of proximal cancer in patients &lt;60 years without a mass or IDA was 0.09% (11/11828). <h3>Conclusion</h3> Patients without mandatory reasons for immediate WCI after a normal flexible sigmoidoscopy (particularly those aged &lt;60 years) should be offered a treat watch and wait diagnostic strategy rather than immediate WCI. NICE guidelines may be encouraging over investigation of patients by WCI. <h3>Disclosure of interest</h3> None Declared.
Expansion of Th1-like Vγ9Vδ2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid
Authors: T Harada, H Miki, Q Cui, A Oda, R Amachi, J Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, S Fujii, S Nakamura, K Kagawa, S Yoshida, I Endo, K Aihara, S Ozaki, T Matsumoto, M Abe
Journal: Leukemia (2016)
Patterns of Total Costs of Care over Time for Patients with Multiple Myeloma (MM)
Authors: Steven R Arikian, Gary Binder, Craig Gibson, X Henry Hu, Yasir Nagarwala, Mohamad A. Hussein, Frank A. Corvino, Jianyi Lee, Andy Surinach, Satyin Kaura, Saad Usmani
Journal: Blood (2015)
Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.
Authors: Ruben Carrasco, Giovanni Tonon, Cameron Brennan, Alexei Protopopov, Raktim Sinha, Bin Feng, Christopher Leo, Yunyu Zhang, Jean Zhang, Fenghuang Zhan, Marina Protopopova, Constantine Mitsiades, Nikhil Munshi, Lynda Chin, Peter Bergsagel, Michael Kuehl, John Shaughnessy, Kenneth Anderson, Ronald DePinho
Journal: Blood (2004)
Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications
Authors: M. Kaminski, L. Rosen, D. Gordon, M. Zheng, Y. J. Hei
Journal: Journal of Clinical Oncology (2004)

857 Background: We previously reported the long-term efficacy and safety of 4 mg zoledronic acid (Zol) compared with 90 mg pamidronate (Pam) in patients with breast cancer or multiple myeloma (Rosen et al. Cancer. 2003;98:1735–1744). Because patients who experience a skeletal-related event (SRE) appear to have an increased risk of subsequent SREs, we performed a retrospective exploratory analysis to assess the benefit of zoledronic acid in patients with a history of SREs before study entry. Methods: An SRE was defined as pathologic fracture, spinal cord compression, radiotherapy or surgery to bone, or hypercalcemia. Patients were retrospectively stratified based on whether they had an SRE before study entry, and the occurrence of SREs on study (over 25 months) was analyzed. Results: A total of 1,122 patients were randomized to Zol or Pam; 691 completed the 13-month core phase, and 417 entered the 12-month extension phase. Before study entry, 760 (68%) patients had experienced at least 1 SRE, and these patients had a 2-fold higher risk of developing an SRE on study than patients with no prior SRE (hazard ratio = 2.08) Across treatment groups, ∼58% of these patients had at least 1 SRE on study versus only ∼32% patients with no SRE before study entry. Among patients with an SRE before study entry, Zol was significantly more effective than Pam at reducing the occurrence of on-study SREs. Andersen-Gill multiple event analysis showed that Zol reduced the risk of SREs by an additional 20% compared with Pam (risk ratio = 0.8; P = .009). In addition, 54% of patients in the Zol group compared with 62% in the Pam group had an SRE on study (P = .032), and the mean skeletal morbidity rate was 1.23 events/yr in the Zol group versus 1.70 events/yr in the Pam group (P = .026). Zol also significantly delayed median time to first SRE by 3.5 months in this subgroup (296 days versus 196 days for the Pam group; P = .029). Conclusions: This exploratory analysis suggests that patients with a history of SREs are at significantly higher risk of subsequent skeletal complications, and Zol was significantly more effective than Pam at reducing SREs in this subgroup. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Corp. Novartis Pharmaceuticals Corp.
Prospective Evaluation of 4T’s Score and Rapid Particle Gel Immuno-Assay Specific to H/PF4 Complexes To Exclude Heparin-Induced Thrombocytopenia.
Authors: Claire Pouplard, Marc Fouassier, Catherine Ternisien, Pierre Gueret, Marc Trossaert, Sandra Regina, Yves Gruel
Journal: Blood (2005)
Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype
Authors: Luca A Lotta, Haifeng M Wu, Marie A Scully, Marina Noris, Agnes Veyradier, Ian J Mackie, Giuseppe Remuzzi, Paul Coppo, Ri Liesner, Roberta Donadelli, Chantal Loirat, Richard A Gibbs, April Horne, Shangbin Yang, Roberta Palla, Flora Peyvandi
Journal: Blood (2011)
TCT-768 Comparative Branch And Distally Focused Main Renal Artery Denervation With Two Radio Frequency Catheters In A Preclinical Model
Authors: Felix Mahfoud, Catherine Pipenhagen, L.B. Moon, James A. Jensen, Atul Pathak, Vasilios Papademetriou, Konstantinos P. Tsioufis
Journal: Journal of the American College of Cardiology (2015)
GW27-e0531 Single nucleotide polymorphism of Methylenetetrahydrofolate reductase (MTHFR) gene and its relationship with serum Homocysteine levels in young Coronary artery disease patients of South-India.
Authors: Latheef Kasala, Rajasekhar Durgaprasad, Vanajakshamma Velam, Sarma PVGK, Aparna R. Bitla, Abhijit Chaudhury, Vasudeva Chetty Pakala
Journal: Journal of the American College of Cardiology (2016)
Routine scans for lymphoma produce minimal radiation-related cancer mortality risk
Authors: P. Shenoy, R. Halkar, S. Wilson, C. Flowers
Journal: Journal of Clinical Oncology (2008)

17508 Background: Recent concern regarding the risks of cancer and cancer-related death due to radiation from computed tomography (CT) scans (Brenner, NEJM 2007) is accompanied by increased use of 18FDG positron emission tomography (PET) scans in lymphoma (Cheson, JCO 2007). We compared the radiation-related lifetime cancer mortality risks (LCMR) associated with CT and PET scans for staging and monitoring of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) with the probability of cancer death during this monitoring period. Methods: Using NCCN Guidelines for HL and NHL, we determined the number of scans a patient would undergo in the 5 years after diagnosis. We utilized published estimates of the cumulative organ-specific radiation doses from full-body CT scans (Brenner, Radiology 2004) and PET (Brix, J Nucl Med 2005), and calculated the lifetime cancer mortality risk (LCMR) associated with scans, using sex-, age-, and organ-dependent cancer risks per 0.1Gy provided by the Biological Effects of Ionizing Radiations VII report. Site-specific cancer risks were summed to yield the overall LCMR as described by Brenner (Med Phys 2001). To provide a comparator for the LCMRs, Surveillance, Epidemiology, and End Results data were used to identify cases between 1973 and 2004 and calculate cumulative probability of cancer death (CPCD) for the specified cohorts. Results: Since LCMR depends on gender and age at exposure, the table shows the LCMRs for CT and PET scans and CPCD for lymphoma subtypes by age at diagnosis. LCMRs were lower for males, were markedly less than the CPCD at 5-years for most lymphoma patients, but become relevant for younger women with HL undergoing CTs given their low risk of cancer death. Although PET scans are not recommended for lymphoma surveillance, they have a reduced LCMR due to less radiation exposure. Conclusions: While the LCMR from scans is small compared to cancer-related deaths for most individuals, these data should be discussed with patients in formulating plans for surveillance following lymphoma therapy. Lymphoma Subtype (Age at Diagnosis) LCMR from CT * LCMR from PET * 5-year Cumulative Probability of Cancer Death Males Females Males Females Males Females NHL (70 yrs) 0.58 0.80 0.33 0.42 46% 42% FL (70 yrs) 0.58 0.80 0.33 0.42 30% 27% DLBCL (70 yrs) 0.58 0.80 0.33 0.42 55% 53% HL (20 yrs) 1.27 1.95 0.61 0.83 13% 8% HL (80 yrs) 0.35 0.47 0.21 0.27 68% 61% * deaths per 100 persons exposed to the cumulative radiation dose associated with scans at 5 years No significant financial relationships to disclose.
Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response
Authors: Philipp Kickingereder, Michael Götz, John Muschelli, Antje Wick, Ulf Neuberger, Russell T. Shinohara, Martin Sill, Martha Nowosielski, Heinz-Peter Schlemmer, Alexander Radbruch, Wolfgang Wick, Martin Bendszus, Klaus H. Maier-Hein, David Bonekamp
Journal: Clinical Cancer Research (2016)

Antiangiogenic treatment with bevacizumab, a mAb to the VEGF, is the single most widely used therapeutic agent for patients with recurrent glioblastoma. A major challenge is that there are currently no validated biomarkers that can predict treatment outcome. Here we analyze the potential of radiomics, an emerging field of research that aims to utilize the full potential of medical imaging.A total of 4,842 quantitative MRI features were automatically extracted and analyzed from the multiparametric tumor of 172 patients (allocated to a discovery and validation set with a 2:1 ratio) with recurrent glioblastoma prior to bevacizumab treatment. Leveraging a high-throughput approach, radiomic features of patients in the discovery set were subjected to a supervised principal component (superpc) analysis to generate a prediction model for stratifying treatment outcome to antiangiogenic therapy by means of both progression-free and overall survival (PFS and OS).The superpc predictor stratified patients in the discovery set into a low or high risk group for PFS (HR = 1.60; P = 0.017) and OS (HR = 2.14; P < 0.001) and was successfully validated for patients in the validation set (HR = 1.85, P = 0.030 for PFS; HR = 2.60, P = 0.001 for OS).Our radiomic-based superpc signature emerges as a putative imaging biomarker for the identification of patients who may derive the most benefit from antiangiogenic therapy, advances the knowledge in the noninvasive characterization of brain tumors, and stresses the role of radiomics as a novel tool for improving decision support in cancer treatment at low cost. Clin Cancer Res; 22(23); 5765-71. ©2016 AACR.
Observacional Study for Evaluation of Quality of Life in Patients with Chronic Myeloid Leukemia (CML) in Use of Gleevec® (Imatinib Mesilate).
Authors: Ricardo Pasquini, Nelma C. Clementino, Maria A. Zanichelli, Alexandre Nonino, Acy T. Quixadá, Carlos Chiattone, Ana D. Freire, Libia P. Villela, Iê R. Bentes, Waldir V. Pereira, Lucia Silla, Iara Zaparoli, Márcia M. Bisterço, Cármino A. De Souza, Vergílio Colturato, Íris Massaut, Eduardo M. Rego, Claudia Vasconcelos
Journal: Blood (2004)
Androgen receptor (AR) overexpression and sensitivity to hormones reversed by epigenetic therapy that restores Purα to a transcriptional repressor complex (RC) of AR deregulated in hormone refractory prostate cancer (HRPC)
Authors: A. C. Ferrari, L. G. Wang, E. M. Johnson, Y. Kinoshita, J. S. Babb, M. T. Buckley, L. F. Liebes, J. Melamed, X. Liu, X. Liu, L. Ossowski
Journal: Journal of Clinical Oncology (2008)

5065 Background: We identified Purα as a crucial component of a transcriptional RC that binds to specific sequences in the 5’-UTR of the AR gene (ARS). Purα knockdown in androgen-dependent (AD) LNCaP cells and forced expression in an androgen- independent-derivative (AI) established the loss of Purα is determinant of AR overexpression and AI growth (Can Res.2008). We have now analyzed: 1. Purα expression and binding to the ARS in hormone naïve (HN) and HR-PC tissues. 2. The effect of histone deacetylase inhibitors (HDACI) on Purα and AR expression and resistance of AI LNCaP cells to hormones. Methods: Tissue Microarray immunohistochemistry (IH), real time PC (QPCR), Oncomine analysis and ChIP assays were used for analysis of Purα and AR expression in tissues. MTT, Western, and EMSA measured the effect on growth and targets of HDACI’s ± casodex treatment of AD and AI LNCaP cells. Results: AR was predominantly nuclear in all tumors with significantly lower (p=0.011) IH staining intensity in HN (mean ±SD=15.4±16.4) than HR (24.4±17.8). The percentage of Purα positive nuclei was significantly lower (P=0.005) for HR (mean ±SD=34.1±37.9; median =12.0) than HN tumors (mean ±SD=80.5±37.2; median=100). AR mRNA levels by QPCR were significantly (p= 0.0317) lower in HN versus HR tumors (mean ±SD=4,172.1±5,992.0 and 52,341.0±102,570.0, respectively) while Purα-mRNA levels were significantly (p=0.0317) higher (5,282.3±6,498.4 and 1.764.5±1.055.6) respectively. An Oncomine database showed similar Purα-mRNA pattern. Purα bound to the ARS-containing DNA sequence by Q-ChIP was 4-fold lower in 3 HR (one sided p = 0.029) than 4 HN tumors. Treatment of AI cells with LBH589 or SAHA restored Purα binding to the RC, reduced AR mRNA levels and growth. The HDACI-bicalutamide combinations were highly synergistic at low concentrations. Conclusion: Loss of Purα binding from a novel transcriptional RC of AR is linked to AR mRNA and protein overexpression in HRPC and LNCaP cells with AI growth. HDACI’s that restore Purα and decrease AR mRNA levels reverse the resistance to antiandrogens. These combinations may translate into a new strategy for hormonal manipulation of AI PC. No significant financial relationships to disclose.